Skip to main content

Table 5 CMR Characteristics at baseline

From: Myocardial involvement in children with post-COVID multisystem inflammatory syndrome: a cardiovascular magnetic resonance based multicenter international study—the CARDOVID registry

  Total
n = 111
Myocarditis
(Group 1)
(n = 20)
No myocarditis (Group 2)
(n = 91)
p-value
Delay symptom onset-CMR, days (n = 109) 28 (19–47) 27 (17–34) 28 (19–50) 0.330
T2 BB 18/110 (16) 11/20 (55) 7/90 (8)  < 0.001
LGE 22/110 (20) 18/20 (90) 0/90  < 0.001
LVEF (%) 58 (55–63) 59 (51–63) 58 (55–63) 0.524
LVEF < 55% (no. of pts) 21/105 (20) 5/19 (26) 16/86 (19) 0.527
LVEDVI (ml/m2) 77.4 ± 15.3 76.8 ± 15.3 77.6 ± 15.4 0.853
LVESVI (ml/m2) 32 (27–38) 34 (25–43) 32 (27–37) 0.464
RVEF (%) 57.3 ± 6.2 56.4 ± 7.8 57.5 ± 5.8 0.519
RVEDVI (ml/m2) 74.0 ± 14.3 77.1 ± 12.4 73.2 ± 14.7 0.325
RVESVI (ml/m2) 33.2 ± 9.6 35.6 ± 9.8 32.7 ± 9.6 0.290
Pericardial effusion (no. pts) 18/89 (20) 5/10 (50) 13/79 (16) 0.026
  1. Bold p values were significative
  2. Values are presented as absolute numbers (%), medians (IQR) or mean (± sd) as appropriate. The denominator for each field is reflective of the total number of available data entry points. CMR  cardiac magnetic resonance, T2 BB  T2 black blood sequence, LGE  late gadolinium enhancement, LVEF  left ventricular ejection fraction, LVEDVI  left ventricular end diastolic volume indexed for body surface area (BSA), LVESVI  left ventricular end systolic volume indexed for BSA, RVEF  right ventricular ejection fraction, RVEDVI  right ventricular end diastolic volume indexed for BSA, RVESVI  right ventricular end systolic volume indexed for BSA, pts patients